Pharmaceutical manufacturer Akums launched India's first indigenous hydroxyurea oral solution, which is used for the treatment of sickle cell disease in children.

Science and Technology

Pharmaceutical manufacturer Akums launched India's first indigenous hydroxyurea oral solution, which is used for the treatment of sickle cell disease in children. The drug will be provided to the government at the cost of R600, which is nearly 1% of the R77,000 that the medicine currently available globally costs. The new formulation offers a cost-effective alternative to imported brands in the country. Designed for ease of use across all age groups suffering from sickle cell disease, Hydroxyurea oral suspension will be offered as oral syringes to guarantee precise dosage, enhancing patient compliance and treatment efficacy.


      Akums’ novel oral suspension drug will be available for Rs600, making it highly accessible to patients.

     

     

 

     


          ____________________________